Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2000

View Archived Issues

Carvedilol surpasses metoprolol in long-term heart failure treatment

EPTTCO and Onyx establish agreement for anticancer agents

Etanercept is well tolerated and efficacious as psoriatic arthritis and psoriasis treatment

Secretin studies in autism reported at pediatric gastroenterology conference

Showa Yakuhin to market CollaGenex's Periostat in Japan

Vion receives NCI research contract to explore TAPET in tumor imaging

Biomira initiates phase IIb trial of BLP25 vaccine

Protein implicated in Ebola virus toxicity

Spherons potentially linked to Alzheimer's disease

Retinoid supplementation improves mouse model of childhood blindness

Mice bred to develop neurofibrillary tangles for dementia research

Access to Kaletra early access program expanded for HIV patients

Prous Science selected official internet and multimedia provider for XXII ESC Congress

Glutamate/serotonin interactions in prefrontal cortex explored

Maxim and Roche to develop combination therapy for hepatitis C and cancer

Theratechnologies to begin PDT trial in Canada

Elan and Pharmacia to collaborate on developing beta-secretase inhibitors

New compounds at Aventis show activity against Gram-positive bacteria

Factor Xa inhibitors under study at Aventis useful for thromboembolic diseases

Tachykinin antagonists discovered at Nippon Zoki

Novel isochroman compound useful for Alzheimer's disease

Janssen receives patent for new antihistaminic series

New compounds interacting with 5-HT6 receptors under development at Merck KGaA

New farnesyl protein transferase inhibitors useful for various tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...